What changed in the data
Pfizer said sigvotatug vedotin failed to improve overall survival in patients with advanced lung cancer that could not be surgically removed. A subsequent analysis of the same study, unveiled Sunday at the European Society for Medical Oncology, indicated a different picture for a smaller subgroup: among individuals with fewer prior treatments before receiving the drug, survival topped chemotherapy by over two months.
Pfizer picked up sigvotatug vedotin in its $43 billion deal for Seagen and had viewed it as a potential first entrant in a new type of medicine that aims powerful cancer-killing agents straight at tumors. The initial miss was a setback, but the follow-on analysis keeps the door open.
Why Pfizer still sees upside
"For patients who are living less than a year, two and a half months is actually very meaningful," said Jeff Legos, Pfizer's chief oncology officer, in an interview at the meeting. He said the next swing is earlier in the disease, where patients have had fewer treatments and their immune system should be stronger, with the aim that pairing therapies will stack their benefits.
Pfizer is running a phase 3 study combining sigvotatug vedotin with Merck's Keytruda in non-small cell lung cancer. Legos said additional early data indicate robust response rates. "For all of those reasons, we remain incredibly enthusiastic about the ongoing phase 3 clinical trial," he said.
When news raises questions about the road ahead, sign up for our free Market Briefs to get clear context.
What it means for your portfolio
The picture is mixed: the study did not show a survival gain overall, yet a cleaner signal in less pretreated patients supports the combination strategy. If the phase 3 trial with Keytruda confirms an additive effect in that earlier setting, Pfizer could still build a lung cancer foothold from an asset many discounted after the initial result. Watch for updates from the ongoing combo trial and any new response data that reinforce the early signs.
If you want a quick, reliable way to check market and economic context, try our free Market Briefs newsletter.
